CLINICAL EVALUATION OF CS-807
スポンサーリンク
概要
- 論文の詳細を見る
CS-807, a new orally absorbed pro-drug of R-3763, was evaluated for its clinical efficacy in five cases of acute bronchitis, one case of chronic bronchitis and 3 cases of acute cystitis.<BR>CS-807 was administered orally at a daily dose of 200mg in two divided doses. The duration of treatment ranged from 5-20 days, and the total dose from 1.0g-4.0g.<BR>The clinical effects were excellent in two, good in six and poor in one case.<BR>Bacteriologically, strains of β-<I>streptococcus</I>, <I>E. coli</I> and <I>S. epidermidis</I> were eliminated.<BR>Neither side-effects nor abnormal laboratory values were observed.<BR>Our results suggest that CS-807 is an effective and safe drug against infectious diseases.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.